Skip to main content

Table 5 Adverse events in all patients (n = 134)

From: Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients

Adverse event

G0

G1

G2

G3

G4

NE

All grades (%)

Grade 3/4 (%)

Leucocyte

9

8

21

44

49

3

91.0

69.4

Neutrophils

9

7

17

30

67

4

90.3

72.4

Hemoglobin

27

41

38

23

2

3

77.6

18.7

Platelets

55

21

18

24

13

3

56.7

27.6

AST

87

38

3

3

0

3

32.8

2.2

ALT

82

35

9

5

0

3

36.6

3.7

Anorexia

52

59

15

2

0

6

56.7

1.5

Nausea

65

49

14

1

0

5

47.8

0.7

Vomiting

103

22

4

0

0

5

19.4

0.0

Diarrhea

112

13

2

2

0

5

12.7

1.5

Fatigue

50

59

15

6

0

4

59.7

4.5

Febrile neutropenia

120

0

0

13

0

1

9.7

9.7

Fever

97

22

12

1

0

2

26.1

0.7

Infection

118

4

5

5

1

1

11.2

4.5

Dyspnea

124

4

1

4

0

1

6.7

3.0

Interstitial pneumonia

124

4

1

4

0

1

6.7

3.0

Neuropathy

128

0

5

0

0

1

3.7

0.0

Rash

114

6

8

5

0

1

14.2

3.7

Edema

131

2

1

0

0

0

2.2

0.0

Mucositis

130

1

3

0

0

0

3.0

0.0

Allergic reaction

132

0

2

0

0

0

1.5

0.0

  1. AST aspartate transaminase, ALT alanine aminotransferase